Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 223-810-8 | CAS number: 4083-64-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No studies available, toxicokinetic assessment based on physical/chemical parameters
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Background
PTSI is extremely reactive with water/moisture, the molecule reacts instantaneously and exothermic to create p-toluenesulfonyl amide (PTSA) under production of carbon dioxide (CO2). The reaction is not pH specific and will take place in any aqueous medium. Due to this extreme reactivity, the toxicokinetic assessment is performed on PTSA instead of PTSI.
No study is available addressing the toxicokinetics of PTSA. Therefore, the toxicokinetic assessment is based on the physical/chemical properties of PTSA.
Physical/chemical properties
PTSA is a strong organic acid (solid) that is soluble in water, alcohols, and other polar organic solvents. The following physical/chemical properties are of interest for assessing the toxicokinetics:
· Water solubility 3.1 g/L
· Molecular weight: 171.23
· Log Kow: 0.6
· Vapour pressure:<2.86.10-7kPa
Absorption
PTSA is hydrophilic (based on the high water solubility) and relatively small (low molecular weight; Mw <500). Therefore oral/GI-absorption by passive diffusion is expected to be high. In a 90-day repeated dose oral toxicity, PTSA was found to cause a treatment-related reduction in body weight gain and minimal urethelial hyperplasia at the highest dose level of 767 mg/kg bwt/day. This finding indicates that oral absorption had occurred.
Respiratory exposure to PTSA is unlikely to occur on a large scale, due to the very low vapour pressure of the substance (<2.86.10-7kPa). However, some respiratory exposure may occur. Any inhaled PTSA may be absorbed through the inhalation tract to the same extent and for the same reasons as for oral absorption.
After dermal exposure, dermal absorption is indicated due to the liquid state of the reaction product of PTSI and the low vapour pressure. Although the molecular weight is >100, which is less favourable for dermal uptake, the molecule is not too large as it is <500. Based on the high water solubility of PTSA acid, dermal uptake is expected to be moderate to high. Furthermore, the high water solubility indicates that the substance may readily partition from the stratum corneum into the epidermis. Moreover, the reactivity of PTSI when coming in contact with water may trigger skin irritation, which may favour dermal absorption.
Distribution
The relatively low molecular weight and high water solubility of PTSA favour its distribution throughout the body, especially into the extracellular spaces. Due to its highly hydrophilic character it is anticipated that it will tend to partition readily to aqueous compartments/tissues. It is less likely that it will partition to the adipose tissues and lipophilic layers like the stratum corneum.
Metabolism and excretion
No studies on metabolism and excretion are available. The low molecular weight (Mw<300) and high water solubility of PTSA will favour rapid excretion via the urine.
Conclusions
Although no study addressing the toxicokinetic properties of PTSA is available, it is assumed that it can readily be absorbed via the oral, dermal and inhalation route and will readily distribute throughout the aqueous compartments of the body, based on its physicochemical properties.
For risk assessment, oral and dermal absorption are assumed to be similar (100%). In absence of information on the inhalation route, a default absorption of twice the oral absorption is assumed for inhalation absorption.
It is also assumed that PTSA will be rapidly excreted via the urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
